With the neoadjuvant regimen of pembrolizumab added to dabrafenib and trametinib, survival in BRAF-mutated forms of the highly aggressive cancer can go from months to more than 5 years.
Among patients with unresectable anaplastic thyroid cancer treated with lenvatinib, average survival was prolonged. The study was published as a preprint and has not yet been peer reviewed.